Biognosys and Bruker form partnership to serve global biopharma and biomarker customers
04.01.2023
Biognosys AG and the US Bruker Corporation announced a strategic partnership. Bruker made a majority-ownership investment in Biognosys. With this investment, Biognosys plans to open advanced US proteomics CRO facility for proteomics biomarker and drug discovery and development, and pharmacoproteomics clinical trial support. The company is a Venture Kick and Venture Leaders alum and was named a TOP 100 Swiss Startup and TOP 100 Scale-Up.
 |
 |
The strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics. This is expected to benefit proteomics research, disease biomarker discovery, drug discovery and development, and clinical trials leveraging pharmacoproteomics.
Financial details were not disclosed. J.P.Morgan acted as an exclusive financial advisor to Biognosys. Several of Biognosys' earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.
Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company. Going forward, Biognosys' biomarker and biopharma customers will benefit from additional services as well as its presence in the US.
Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. In particular, the Biognosys TrueTarget™, TrueDiscovery™, and TrueSignature™ research service solutions provide deep, peptide-level proteome insights for drug discovery and development.
The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys' versatile portfolio of proprietary proteomics services, software, and kits, and Bruker's pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.
Biognosys' Spectro high-performance vendor-agnostic proteomics software and their peptide kit solutions
Dr. Oliver Rinner, CEO and Co-Founder of Biognosys, commented: "We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development. We have worked closely with Bruker to support dia-PASEF® high-throughput, deeper proteomics methods within our Spectronaut® software. Biognosys remains committed to maintaining Spectronaut® as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies."
"For over a decade, ETH spin-off Biognosys has translated novel proteomics methods pioneered in our research group into robust, high-performance workflows for large-scale basic and translational research," said proteomics pioneer and member of Biognosys scientific advisory board, Dr. Ruedi Aebersold. "I am delighted that this new partnership between Biognosys and Bruker will further accelerate access to high-performance proteomics. It will also provide opportunities to develop next-generation technology and methods to determine unexplored but functionally relevant dimensions of the proteome, such as the modulation of proteoform composition, and protein interaction networks as a function of cellular state."
In 2009, Biognosys was awarded CHF 30,000 by Venture Kick and was chosen to participate in the Venture Leaders program. The company ranked among the TOP 100 Swiss Startups from 2011 to 2013 and was voted a TOP 100 Swiss Scale-Up in 2019.
Financial details were not disclosed. J.P.Morgan acted as an exclusive financial advisor to Biognosys. Several of Biognosys' earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.
Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company. Going forward, Biognosys' biomarker and biopharma customers will benefit from additional services as well as its presence in the US.
Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. In particular, the Biognosys TrueTarget™, TrueDiscovery™, and TrueSignature™ research service solutions provide deep, peptide-level proteome insights for drug discovery and development.
The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys' versatile portfolio of proprietary proteomics services, software, and kits, and Bruker's pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.
Biognosys' Spectro high-performance vendor-agnostic proteomics software and their peptide kit solutions
Dr. Oliver Rinner, CEO and Co-Founder of Biognosys, commented: "We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development. We have worked closely with Bruker to support dia-PASEF® high-throughput, deeper proteomics methods within our Spectronaut® software. Biognosys remains committed to maintaining Spectronaut® as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies."
"For over a decade, ETH spin-off Biognosys has translated novel proteomics methods pioneered in our research group into robust, high-performance workflows for large-scale basic and translational research," said proteomics pioneer and member of Biognosys scientific advisory board, Dr. Ruedi Aebersold. "I am delighted that this new partnership between Biognosys and Bruker will further accelerate access to high-performance proteomics. It will also provide opportunities to develop next-generation technology and methods to determine unexplored but functionally relevant dimensions of the proteome, such as the modulation of proteoform composition, and protein interaction networks as a function of cellular state."
In 2009, Biognosys was awarded CHF 30,000 by Venture Kick and was chosen to participate in the Venture Leaders program. The company ranked among the TOP 100 Swiss Startups from 2011 to 2013 and was voted a TOP 100 Swiss Scale-Up in 2019.